A growing body of studies supports the concept of “type 3 diabetes,” or brain insulin resistance, which has been suggested to contribute to impaired neuronal glucose utilization, decreased synaptic plasticity, increased tau phosphorylation, and eventually pathology like that seen in Alzheimer’s disease [19]. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.